Showing results (1-10 of 27) with videos related to
Sort By:
Pageof 3
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|December 29, 2005
[Chemotherapy in soft tissue sarcomas]L ZelekAnnals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2000
Is òne cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasmsK Fizazi, L ZelekArchives D'Anatomie Et De Cytologie Pathologiques|January 1, 1995
[Mesenchymal breast sarcomas: general review]M Spielmann, L Zelek, A LlombartHepato-Gastroenterology|July 21, 2001
Chemotherapy of nonoperable colorectal liver metastasesP Piedbois, L Zelek, D CherquiBulletin Du Cancer|September 22, 2010
[Phyllodes tumors and breast sarcomas: a review]J Grenier, C Delbaldo, L Zelek, et al.Studies in Health Technology and Informatics|October 18, 2001
A before-after study using OncoDoc, a guideline-based decision support-system on breast cancer management: impact upon physician prescribing behaviourJ Bouaud, B Séroussi, E C Antoine, et al.Urologic Oncology|February 13, 2001
Metachronous gonadal and extragonadal primaries, or late relapse of germ cell tumor?C Daniel, K Fizazi, S Culine, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2001
Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanesL Zelek, S Barthier, M Riofrio, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2000
Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancerM Spielmann, A Llombart, L Zelek, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 2, 1999
High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patientsP H Cottu, L Zelek, J M Extra, et al.Pageof 3